Testing for ROS1 in non-small cell lung cancer: a review with recommendations
详细信息 查看全文
- 作者：Lukas Bubendorf ; Reinhard Büttner ; Fouad Al-Dayel ; Manfred Dietel…
- 关键词：Fluorescence in situ hybridisation ; Immunohistochemistry ; Non ; small cell lung cancer ; Predictive marker ; ROS1 ; RT ; PCR
- 刊名：Virchows Archiv
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：469
- 期：5
- 页码：489-503
- 全文大小：1,286 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Pathology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-2307
- 卷排序：469
文摘
Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laboratories currently rely on fluorescence in situ hybridisation (FISH) assays using a dual-colour break-apart probe to detect ROS1 rearrangements. Given the rarity of these rearrangements in NSCLC, detection of elevated ROS1 protein levels by immunohistochemistry may provide cost-effective screening prior to confirmatory FISH testing. Non-in situ testing approaches also hold potential as stand-alone methods or complementary tests, including multiplex real-time PCR assays and next-generation sequencing (NGS) platforms which include commercial test kits covering a range of fusion genes. In order to ensure high-quality biomarker testing, appropriate tissue handling, adequate control materials and participation in external quality assessment programmes are essential, irrespective of the testing technique employed. ROS1 testing is often only considered after negative tests for EGFR mutation and ALK gene rearrangement, based on the assumption that these oncogenic driver events tend to be exclusive. However, as the use of ROS1 inhibitors becomes routine, accurate and timely detection of ROS1 gene rearrangements will be critical for the optimal treatment of patients with NSCLC. As NGS techniques are introduced into routine diagnostic practice, ROS1 fusion gene testing will be provided as part of the initial testing package.